These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 18221403)

  • 1. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
    Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
    Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
    Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
    Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
    Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.
    Brady JJ; Crowley RK; Murray BF; Kilbane MT; O'Keane M; McKenna MJ
    Ir J Med Sci; 2014 Mar; 183(1):47-52. PubMed ID: 23737138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of bone resorption markers in hemodialysis patients.
    Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y
    Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
    Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis.
    Nagata Y; Inaba M; Imanishi Y; Okazaki H; Yamada S; Mori K; Shoji S; Koyama H; Okuno S
    Osteoporos Int; 2015 Mar; 26(3):1053-61. PubMed ID: 25403902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
    Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
    J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
    Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
    Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
    Nowak Z; Konieczna M; Wańkowicz Z
    Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new approach for evaluating bone turnover in chronic kidney disease.
    Tolouian R; Hernandez GT; Chiang WY; Gupta A
    Eur J Intern Med; 2010 Jun; 21(3):230-2. PubMed ID: 20493428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cross-linked N-terminal telopeptide of type I collagen for evaluation of renal osteodystrophy in hemodialysis patients.
    Nakashima A; Yorioka N; Mizutani T; Yamagata Z; Ueno T; Takasugi N
    Nephron Clin Pract; 2005; 99(3):c78-85. PubMed ID: 15665550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients.
    Shidara K; Inaba M; Okuno S; Yamada S; Kumeda Y; Imanishi Y; Yamakawa T; Ishimura E; Nishizawa Y
    Calcif Tissue Int; 2008 Apr; 82(4):278-87. PubMed ID: 18421493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
    Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
    Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients.
    Fujimori A; Okada S; Sakai M; Tome K; Fukagawa M
    Nephron Clin Pract; 2011; 118(4):c375-9. PubMed ID: 21325869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.